Eli Lilly Stock (LLY) Faces This Make-or-Break Test on April 10

FomoAnxiety · 2026-03-23T17:18:41+00:00

Eli Lilly's stock is closely watched as the FDA decision on its weight-loss pill Orforglipron approaches on April 10. The approval could significantly boost the company's market share and stock price, currently down 15% in 2026. Analysts maintain a Strong Buy rating, projecting substantial upside.

FomoAnxiety

2026-03-23 17:18:41

Abstract generation in progress

Investors considering taking a position in Eli Lilly LLY +1.49% ▲ stock might want to do so before April 10.

Claim 30% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

stay

SettingsOffArabicChineseEnglishFrenchGermanHindiPortugueseSpanish

Font ColorwhiteFont Opacity100%Font Size100%Font FamilyArialText ShadownoneBackground ColorblackBackground Opacity50%Window ColorblackWindow Opacity0%

WhiteBlackRedGreenBlueYellowMagentaCyan

100%75%50%25%

200%175%150%125%100%75%50%

ArialGeorgiaGaramondCourier NewTahomaTimes New RomanTrebuchet MSVerdana

NoneRaisedDepressedUniformDrop Shadow

WhiteBlackRedGreenBlueYellowMagentaCyan

100%75%50%25%0%

WhiteBlackRedGreenBlueYellowMagentaCyan

100%75%50%25%0%

That’s the date when the U.S. Food and Drug Administration (FDA) is expected to deliver its verdict on the company’s highly-anticipated weight-loss pill Orforglipron. Analysts say the stakes couldn’t be higher for Eli Lilly, especially with its stock trading nearly 20% below their all-time high reached late last year.

Eli Lilly is counting on FDA approval of its weight-loss pill to help it build on its dominant position in the market for obesity treatments. The company currently holds a 60% share of the U.S. market for weight-loss medications. The weight-loss pill is expected to be a gamechanger for Eli Lilly as it will be more palatable to consumers than current obesity drugs that are taken via injection.

LLY Stock Performance

The April 10 FDA deadline looms over Eli Lilly as its share price has declined sharply so far in 2026. After rallying throughout the autumn, LLY stock has slumped 15% this year as investors rotate into safe haven assets and as the broader healthcare market struggles.

Eli Lilly also has ground to make-up after archrival Novo Nordisk NVO +1.53% ▲ launched its competing weight-loss drug Wegovy in late 2025. Should the FDA greenlight Eli Lilly’s oral drug Orforglipron on April 10, LLY stock is expected to soar. The company is already ramping up production of the medication and preparing a global marketing push in anticipation of the FDA approval.

Anything short of full approval from the FDA though and LLY stock could extend its year-to-date decline.

Is LLY Stock a Buy?

The stock of Eli Lilly has a consensus Strong Buy rating among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last three months. The average LLY price target of $1,247.38 implies 31.53% upside from current levels.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes